A clinical study to evaluate the preventive effect of denosumab(Pralia) on bone loss in men receiving androgen-deprivation therapy for prostate cancer.

A clinical study to evaluate the preventive effect of denosumab(Pralia) on bone loss in men receiving androgen-deprivation therapy for prostate cancer. - A clinical study to evaluate the preventive effect of Pralia on bone loss in men receiving ADT for PCa.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015127

Enrollment

Registered

2014-09-12

Start date

2014-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

pralia

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: For prostate cancer patients who recieve ADT

Exclusion criteria

Exclusion criteria: patients who have dental caries and osteonecrosis of the jaw

Design outcomes

Primary

Measure	Time frame
SRE QOL	—

Secondary

Measure	Time frame
bone density marker of bone metabolism pain	—

Countries

Japan

Contacts

Public ContactTakeo Kosaka

Keio University School of Medicine Department of Urology

takemduro@a6.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026